View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 3, 2018

Shire divests oncology business to Servier for $2.4bn

Shire has concluded the divestiture of its Oncology unit to French pharmaceutical company Servier for a total consideration of $2.4bn.

Shire has concluded the divestiture of its Oncology unit to French pharmaceutical company Servier for a total consideration of $2.4bn.

Free Report
img

What was the hiring sentiment across Healthcare in 2021?

by GlobalData
Enter your details here to receive your free Report.

The deal covers global rights to Oncaspar, along with ex-US and ex-Taiwan rights to Onivyde and additional oncology pipeline assets.

Shire Global Genetic Diseases and Oncology franchises former head David Lee will become the CEO of Servier’s new US commercial subsidiary, Servier Pharmaceuticals.

Shire CEO Flemming Ornskov said: “The closing of this transaction demonstrates the value embedded in our portfolio and our continued focus on executing against our strategic priorities.

“I am confident that Servier will continue to bring these important therapies to patients worldwide.”

Servier expects the acquisition to offer the company a direct commercial presence in the US, as well as bolster its oncology portfolio in other countries.

Servier Pharmaceuticals will market the company’s products in the US. The new subsidiary currently has 80 employees and will work towards establishing strong sales presence in the country.

“This acquisition marks the launch of Servier’s commercial activities in the world’s largest pharmaceutical market – the US – and significantly strengthens its portfolio of oncology drugs.”

In markets outside the US, Servier will market Oncaspar and Onivyde and will gain around 75 employees from Shire.

Oncaspar is a component of multi-agent therapy for acute lymphoblastic leukemia (ALL), while Onivyde is intended to treat metastatic pancreatic cancer after gemcitabine-based therapy.

Servier president Olivier Laureau said: “This acquisition is a major step in achieving the Servier group’s ambition. It marks the launch of Servier’s commercial activities in the world’s largest pharmaceutical market – the US – and significantly strengthens its portfolio of oncology drugs.

“It is part of Servier’s twofold strategy: to continue to treat an increasing number of patients with innovative medications across the world and become a world reference in oncology.”

Shire originally entered an agreement to sell the Oncology franchise in April this year as part of its strategy to focus on core areas and the rare diseases market.

Related Companies

Free Report
img

What was the hiring sentiment across Healthcare in 2021?

by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology